Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma

• DOI: 10.1097/sla.0b013e3182602af4
• Publication Date: 2012-06-30T08:57:29Z
• Authors: Bahil Ghanim; Mir Alireza Hoda; Max-Paul Winter; Thomas Klikovits; Arman Alimohammadi; Balazs Hegedus; Balazs Dome; Michael Grusch; Madeleine Arns; Peter Schenk; Wolfgang Pohl; Christoph Zielinski; Martin Filipits; Walter Klepetko; Walter Berger
• Keywords: Radical surgery

To evaluate the prognostic and predictive relevance of pretreatment serum C-reactive protein (CRP) in malignant pleural mesothelioma (MPM) patients.MPM is a rare but aggressive disease with poor treatment outcome. Therapeutic decision challenging, biomarkers for better stratification are urgently needed.Clinical data, including survival CRP levels, were retrospectively collected from 115 patients histologically proven MPM. Patients any evidence infectious excluded. The association between levels was analyzed using Cox models adjusted clinical pathological factors.Median all 1.19 mg/dL (range: 0.00-22.62 mg/dL). elevated (≥1 mg/dL; n = 62, 53.9%) had significantly shorter overall compared those normal (hazard ratio [HR] 2.81, 95% confidence interval [CI] 1.82-4.33; P < 0.001). In multivariate analyses, confirmed as an independent factor MPM (HR 2.07, CI 1.23-3.46; 0.01). Most interestingly, we observed significant interaction modality (P Among radical tumor resection within multimodality therapy associated distinctly prolonged when protocols without surgery 7.26, 3.40-15.49; contrast among CRP, no benefit achieved by approaches 0.911, 0.53-1.58; 0.74).Our results suggest that regimens increase selectively levels.